Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HALAVEN vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Metastatic breast cancer in patients who have received at least two prior chemotherapy regimens including an anthracycline and a taxane,Unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life approximately 30-50 hours (mean 40 hours). Clinically, this supports weekly dosing schedule.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Eribulin is primarily metabolized by CYP3A4 with minor contributions from other CYP isoforms. It undergoes minimal hepatic metabolism and is predominantly excreted unchanged in bile and feces.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Primarily biliary/fecal: ~70-80% as unchanged drug and metabolites in feces; renal excretion accounts for <10% (mostly metabolites).
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Approximately 87-95% bound primarily to albumin and alpha-1-acid glycoprotein.
47% bound to plasma proteins (primarily albumin)
Vd approximately 32-48 L/m² (approx. 0.9-1.4 L/kg, assuming 70 kg). Large Vd indicates extensive tissue distribution.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Only intravenous route available; no oral bioavailability data as it is not administered orally.
IV: 100% (only IV route); oral: not approved
For creatinine clearance 30-50 m L/min: 1.1 mg/m2 on days 1 and 8 of a 21-day cycle. For creatinine clearance <30 m L/min: not recommended.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Child-Pugh A: 1.1 mg/m2 on days 1 and 8 of a 21-day cycle. Child-Pugh B: 0.7 mg/m2 on days 1 and 8 of a 21-day cycle. Child-Pugh C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Safety and efficacy not established in pediatric patients.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment recommended; monitor for toxicity.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
No FDA boxed warning.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Neutropenia: monitor complete blood counts prior to each dose; dose reduce or delay as needed,Peripheral neuropathy: monitor for neuropathy, dose reduce or discontinue if severe,QT prolongation: monitor ECG in patients with heart failure, bradyarrhythmias, or electrolyte abnormalities,Embryo-fetal toxicity: can cause fetal harm, advise effective contraception
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Hypersensitivity to eribulin or any components of the formulation
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
Avoid grapefruit and grapefruit juice as they may increase eribulin levels.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
FDA Pregnancy Category D. Based on its mechanism of action (microtubule inhibitor) and animal studies, HALAVEN can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, eribulin was embryotoxic and fetotoxic at doses below the recommended human dose. There are no adequate and well-controlled studies in pregnant women. If used during pregnancy or if the patient becomes pregnant while receiving this drug, apprise the patient of the potential hazard to the fetus. Avoid use during the first trimester due to high risk of teratogenicity; use during second and third trimesters may cause fetal growth restriction and oligohydramnios.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
It is not known whether eribulin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from HALAVEN, advise women not to breastfeed during treatment and for at least 2 weeks after the last dose. No M/P ratio available.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No specific dosing adjustments for pregnancy have been established. Physiological changes during pregnancy (e.g., increased plasma volume, renal clearance) may alter eribulin pharmacokinetics, but no data exist. Use the standard dose of 1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle, with dose adjustments based on toxicity (e.g., neutropenia, thrombocytopenia, hepatic impairment) rather than pregnancy status.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
Halaven (eribulin) is a nontaxane microtubule inhibitor used in metastatic breast cancer and liposarcoma. Monitor for neutropenia, peripheral neuropathy, and QT prolongation. Dose reduction required for moderate hepatic impairment (Child-Pugh B). Administer intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle. Antiemetic prophylaxis recommended.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
This drug can lower your white blood cell count, increasing infection risk. Report fever or chills immediately.,You may experience numbness, tingling, or weakness in your hands or feet; notify your doctor if these occur.,Halaven can cause fatigue, nausea, and hair loss; supportive care is available.,Avoid grapefruit and grapefruit juice during treatment due to potential interaction.,Use effective contraception during treatment and for at least 2 weeks after the last dose.,Do not breastfeed while taking this medication.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HALAVEN vs CLOFARABINE, answered by our medical review team.
HALAVEN is a Antineoplastic Agent that works by Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HALAVEN and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HALAVEN is: 1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HALAVEN and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HALAVEN is classified as Category C. FDA Pregnancy Category D. Based on its mechanism of action (microtubule inhibitor) and animal studies, HALAVEN can cause fetal harm when administered to a pregnant woman. In animal. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.